Recent Literature Supports That Low Free T3 was the Highest Independent Predictor of Death in CV Patients
Recent Literature Supports That Low Free T3 was the Highest Independent Predictor of Death in CV Patients Written by Neal Rouzier, MD Recommended Pre-Reading: More Proof and Reasoning that T4
More Proof and Reasoning that T4 Monotherapy Results in Inadequate Conversion
More Proof and Reasoning that T4 Monotherapy Results in Inadequate Conversion Written by Neal Rouzier, MD Recommended Pre-Reading: If T4 Does not Improve Symptoms, and Normalizing TSH Does not Guarantee
If T4 Does not Improve Symptoms, and Normalizing TSH Does not Guarantee or Infer Improvement in Symptoms, Then How Should we Treat Patients?
If T4 Does not Improve Symptoms, and Normalizing TSH Does not Guarantee or Infer Improvement in Symptoms, Then How Should we Treat Patients? Written by Neal Rouzier, MD Recommended Pre-Reading:
CVD: Could all the Medicines that we Prescribe, Including Statins, be Increasing the Risk of Cancer?
CVD is the # 1 killer in the U.S. and worldwide. The medical literature and pharmaceutical industry has led us to believe in the cholesterol-centric model in preventing CVD. Unfortunately, utilizing cholesterol-lowering medication has only led to a 1-3% absolute risk reduction (ARR) in CVD and mortality. Not very impressive for all the money and effort put forth in lowering cholesterol with medication. And if the cholesterol-centric model for CVD was 100% correct, then why don’t we witness a more definitive reduction in CVD morbidity and mortality? Is there something else that could be at the root of this disease that we are missing?
The CVD and Cancer Insanity Cycle: What Should we do if What we are Doing Isn’t Working?
As clinicians we try to be problem solvers. It is part of our training, try to figure out what’s wrong, and then to fix it. Problem solved. However, what should we do if what we are doing isn’t working? Keep doing the same thing? What if the patient does not get better? What if the patient doesn’t feel better? What if the incidence of CVD continues to increase despite all the medications we prescribe? What if the incidence of cancer continues to increase even though cancer treatments themselves once you get cancer have improved? It is often said that insanity is doing the same experiment over and over again expecting to see and hoping to see different results.
Hormone Facts You Should Know
Recently the medical community has undergone criticism for journalistic articles and medical studies that promote one drug or treatment over another. There are often political or economic gains behind the purpose or results of the studies, which leads to inappropriate and biased conclusions or recommendations in these articles. This has negatively impacted the credibility of some authors and journals. Some medical journals provide a study rating score so that the reader may be able to discern any bias of a study’s treatment or product. In addition, medical journals and textbooks now use the term “evidence-based medicine” (EBM) in order to assert credibility for a medical treatment based on peer-reviewed studies or meta-analysis. The purpose of this introduction is to prevent the reader from being led astray by the political and economic bias from paid authors of medical journal papers with misleading agendas.
What Healthcare Providers Need to Know About The Women’s Health Initiative (WHI)
If you’ve taken any of Worldlink Medical’s CME courses with Dr. Neal Rouzier, you’ve learned about the hornet’s nest of controversy over prescribing hormones to women in menopause that’s been stirred up over the past two decades. You may be familiar with the landmark 2002 study, The Women’s Health Initiative but you may be a little confused on the results and actual implications of the study results vs what the media reports.
Make a Difference in Patient Wellness with Hormone Therapy
Have you experienced the frustration of a patient who never seems to get better?
You’ve diagnosed them with insulin resistance or even full-blown Type II Diabetes. You’ve counseled them on changing her diet. You’ve prescribed metformin to reduce glucose production in the liver. But on the next visit, their fasting blood glucose hasn’t changed or is even a bit higher. Their hemoglobin A1C isn’t budging. They lost a couple of pounds early on, but gained it back after a few weeks.
You’ve asked her how they are doing with changing the way they eat and they say, “I’m trying.”
Worst of all, your patient is clearly feeling discouraged. They are ready to give up. “What’s the use?”
If you’ve ever experienced this scenario, you’re not alone. This frustration comes up all the time in our discussions with providers at our BHRT Workshop Series.
Treating T3 Deficiency, the Evidence You Need
I do not believe that there is any one subject in medicine that is as misunderstood, politicized, debated, denigrated, and contentious as thyroid hormone. The pharmaceutical thyroid industry has spent millions on brain-washing physicians and convincing them that thyroxine is the best and only thyroid medicine that should be utilized. So many patients have relayed to me that their PMD will no longer treat them if they continue to take Armour Thyroid.
How Hormones are Disrupting the Oncology Industry
Why is there increased morbidity and mortality in those that don’t take ERT? This is simply because there is an increase in breast cancer recurrence in prior cancer survivors, around 350/10,000 women (that don’t take HRT). This does not mean, though, that taking estrogen increases the risk. However, those that do take BHRT do benefit from HRT despite the resistance from oncologists. The increase in breast cancer recurrence at baseline should not be extrapolated to what happens with treatment. In every study, treatment with estrogen decreases breast cancer risk. Observation at baseline does not prove causation. The most recent issue of JAMA proved that the only drug to decrease breast cancer mortality was estrogen! It was not a SERM or AI.